Biotech RadarJobs updated

COMPANY

Annovis Bio Inc.

HQ: Malvern, PA source · annovisbio.com ↗ · Mid-Atlantic

Clinical Phase 3

Annovis is a Phase 3 clinical-stage company developing therapies for neurodegenerative disease such as Alzheimer's disease (AD) and Parkinson's disease (PD). From company website Source · Oct 12, 2026

Keywords: Alzheimer Disease Parkinson's Disease Deep Brain Stimulation Alzheimer's Dementia Early Alzheimers Disease Idiopathic Parkinson's Disease Parkinson Disease Amnestic Mild Cognitive Impairment buntanetap/posiphen

Location: Malvern, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$46.0MRaised (2 yrs)8Trials (company is sponsor)3NIH grants

Timeline

  1. Trial start Phase 2/Phase 3: An Open-label Long-term Safety Study of Buntanetap in Participants With AD source ↗
  2. Raise Follow-on offering: $15M (total, as published), announced May 20, 2026. Source: SEC filing. source ↗
  3. Raise Follow-on offering: $10M (total, as published), announced Apr 9, 2026. Source: SEC filing. source ↗
  4. Trial start Phase 2/Phase 3: A Study of Buntanetap in Participants With PD source ↗
  5. Raise Follow-on offering: $21M (total, as published), announced Feb 4, 2025. Source: SEC filing. source ↗
  6. Trial start Phase 3: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD source ↗
  7. Trial start Phase 2/Phase 3: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD source ↗
  8. Trial start Phase 3: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD source ↗
  9. Trial start Phase 1/Phase 2: Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients source ↗
  10. Trial start Phase 1/Phase 2: Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease source ↗
  11. Trial start Phase 1: Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $46.0M. Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT07284784A Study of Buntanetap in Participants With PDPhase 2/Phase 3RecruitingJan 9, 20262029-09 (estimated)
NCT07757204An Open-label Long-term Safety Study of Buntanetap in Participants With ADPhase 2/Phase 3Not yet recruitingSep 21, 2026Feb 21, 2030 (estimated)
NCT06709014A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADPhase 3Active, not recruitingFeb 4, 20252027-12 (estimated)
NCT05686044A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADPhase 2/Phase 3CompletedApr 1, 2023Feb 13, 2024 (actual)
NCT05357989A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDPhase 3CompletedAug 3, 2022Dec 4, 2023 (actual)
NCT02925650Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's DiseasePhase 1/Phase 2CompletedMar 2, 2017Dec 10, 2021 (actual)
NCT04524351Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's PatientsPhase 1/Phase 2CompletedAug 14, 2020Aug 16, 2021 (actual)
NCT01072812Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive ImpairmentPhase 1Terminated2010-022010-07 (actual)

NIH awards 3

Annual award amounts. Total $2.1M.

Feedback